Sinovation

Sinovation (Beijing) Medical Technology Co., Ltd. stands as China’s leading neurosurgical robotics company, originating from collaborative research with Tsinghua University’s Department of Biomedical Engineering. The company has built a broad technology platform covering surgical robots, navigation systems, intracranial electrodes, and laser ablation therapy, serving over 200 medical institutions across China.

Company Overview

Founded in 2015, Sinovation emerged from two decades of neurosurgical technology research led by Professor Guangzhi Wang at Tsinghua University. The company achieved a significant expansion in 2022 through the acquisition of Beijing Huake Hengsheng Medical Technology Co., Ltd. (HKHS), the world’s third-largest intracranial electrode manufacturer and China’s first company to commercialize intracranial EEG signal acquisition consumables.

Sinovation has secured strategic investment from global medical device leader Medtronic and domestic neuromodulation pioneer PINS Medical (Beijing), alongside venture capital from Kaifeng Ventures, Northern Light Venture Capital, and Denovo Capital. The company has completed multiple funding rounds totaling over ¥500 million, with the most recent D+ round exceeding ¥100 million. As of 2025, Sinovation has initiated IPO preparations.

The company holds National Specialized and Sophisticated “Little Giant” Enterprise status, has accumulated over 260 core invention patents, and has received 11 NMPA Class III medical device registration certificates. Four products have entered NMPA’s Special Review Channel for Innovative Medical Devices.

Core Products

Sinobot X1 (SR Series)

The flagship neurosurgical robot featuring proprietary Holoshot 3D structured light registration technology. This system eliminates the need for marker placement and pre-operative CT scanning, reducing patient registration time to under 3 minutes. The Sinobot X1 received both NMPA approval through the innovative device channel and FDA 510(k) clearance in June 2023, making it the only Chinese neurosurgical robot with FDA approval.

Q300 Series

A compact neurosurgical robot weighing approximately 1.4 kg, designed for broader hospital adoption. The system integrates rapid laser surface scanning registration and infrared optical tracking, achieving sub-millimeter positioning accuracy while supporting both stereotactic puncture and craniotomy navigation procedures. Approved through NMPA’s innovative device channel in early 2022.

X1000 Series

China’s first brain and spine surgical robot system, approved in September 2024. This platform uniquely combines neurosurgical robot positioning, neurosurgical navigation, and spinal surgical robot navigation in a single integrated system, covering applications from intracranial tumors and hemorrhage to cervical, thoracic, and lumbar spine procedures.

LS Series (LITT)

The MRI-guided laser interstitial thermal therapy system received NMPA approval in April 2023, becoming the first and only domestically-developed brain laser ablation system approved in China. The system enables real-time intracranial temperature monitoring and provides minimally invasive treatment options for epilepsy and brain tumor patients unsuitable for open surgery.

HKHS Electrode Series

Through its subsidiary HKHS, Sinovation offers intracranial electrode products including cortical electrodes, depth electrodes, thermocoagulation electrodes, and sphenoidal electrodes. Annual sales volume reaches tens of thousands of units across over 200 Class A tertiary hospitals, achieving domestic market leadership and import substitution.

Technology & Innovation

Sinovation’s core technological differentiator lies in its 3D structured light registration system, which fundamentally reimagines patient registration in neurosurgery. Traditional optical probe-based positioning requires marker placement and additional CT scanning, introducing potential errors and extending preparation time. The Holoshot technology performs automatic visual scanning of the patient’s facial surface, establishing precise spatial coordination without markers.

The company’s SinoPlan surgical planning software, approved by NMPA in 2024, represents China’s first domestically-developed neurosurgical planning system with independent intellectual property. The software supports various devices including stereotactic frames and surgical robots, enabling full 3D modeling, vascular avoidance planning through AngioRender and SurgeonEye technologies, and simulated resection of skin, skull, vessels, and brain parenchyma.

In 2025, Sinovation received NMPA approval for the ES-100, a 7-axis robotic surgical microscope featuring intelligent follow-through, 4K-3D high-definition imaging, and enhanced fluorescence capabilities for improved precision in brain tumor surgery.

Market Presence

Sinovation’s products serve over 200 medical institutions nationwide, with the company holding a leading position in the domestic neurosurgical robot market. Combined with Remebot, these two Chinese companies command over 80% of the neurosurgical robot market share in China.

The Sinobot X1’s FDA clearance opened international market access, marking a significant milestone for Chinese surgical robotics. The company has established technical service capabilities supporting both high-tier hospitals and grassroots medical facilities, offering a full spectrum of solutions from diagnosis and surgical planning to intraoperative navigation and real-time monitoring treatment.

Clinical applications span major neurosurgical conditions including epilepsy (SEEG electrode implantation), Parkinson’s disease (DBS electrode placement), cerebral hemorrhage, brain tumors, and trigeminal neuralgia. The surgical robot has demonstrated particular value in SEEG procedures, where multiple electrode implantation requirements benefit significantly from robotic precision and efficiency, reducing implantation time by over 60%.

Key Milestones

• 2015: Company founded, collaborating with Tsinghua University on neurosurgical robot development
• 2017: Entered NMPA’s Special Review Channel for Innovative Medical Devices
• 2018: SR1 series neurosurgical robot received NMPA approval
• 2020: Completed Series C funding of several hundred million yuan
• 2022: Acquired HKHS, expanded to intracranial electrode business; Q300 series approved
• 2022: Completed Series D funding of nearly ¥300 million
• 2023 (April): LITT laser ablation system received NMPA approval
• 2023 (June): Sinobot X1 became first Chinese neurosurgical robot with FDA clearance
• 2024: Completed Series D+ funding exceeding ¥100 million
• 2024 (September): X1000 brain and spine robot approved by NMPA
• 2025: Initiated IPO process; ES-100 robotic microscope approved

Frequently Asked Questions

What products does Sinovation offer?

Sinovation provides neurosurgical solutions including the Sinobot X1 neurosurgical robot (FDA-approved), Q300 compact robot, X1000 brain-spine robot, LS series LITT laser ablation system, NS navigation systems, and HKHS intracranial electrodes. The company has received 11 NMPA Class III registrations.

Is Sinovation publicly traded?

As of early 2026, Sinovation remains a private company but has initiated IPO preparations. The company has completed multiple funding rounds totaling over ¥500 million, with investors including Medtronic, PINS Medical, Kaifeng Ventures, Northern Light Venture Capital, and Denovo Capital.

What makes Sinovation’s technology unique?

Sinovation developed the world’s first 3D structured light neurosurgical robot, which eliminates marker placement and pre-operative CT requirements for patient registration. The Holoshot technology reduces registration time to under 3 minutes while improving accuracy. The Sinobot X1 is the only Chinese neurosurgical robot with FDA clearance.

Which conditions can Sinovation’s robots treat?

The robots support procedures for epilepsy (SEEG electrode implantation), Parkinson’s disease (DBS electrode placement), cerebral hemorrhage evacuation, brain tumor biopsy, trigeminal neuralgia, and with the X1000 series, spinal procedures including pedicle screw fixation and vertebroplasty.